Deciphering of Adult Glioma Vulnerabilities through Expression Pattern Analysis of GABA, Glutamate and Calcium Neurotransmitter Genes.

GABA amino acid neurotransmission calcium glioma glutamate methylation transcriptomics tumor immune microenvironment

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
14 Apr 2022
Historique:
received: 01 02 2022
revised: 02 04 2022
accepted: 11 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

Adult infiltrating gliomas are highly aggressive tumors of the central nervous system with a dismal prognosis despite intensive multimodal therapy (chemotherapy and/or radiotherapy). In this study, we studied the expression, methylation and interacting miRNA profiles of GABA-, glutamate- and calcium-related genes in 661 adult infiltrating gliomas available through the TCGA database. Neurotransmitter-based unsupervised clustering identified three established glioma molecular subgroups that parallel major World Health Organization glioma subclasses (IDH-wildtype astrocytomas, IDH-mutant astrocytomas, IDH-mutant oligodendroglioma). In addition, this analysis also defined a novel, neurotransmitter-related glioma subgroup (NT-1), mostly comprised of IDH-mutated gliomas and characterized by the overexpression of neurotransmitter-related genes. Lower expression of neurotransmission-related genes was correlated with increased aggressivity in hypomethylated IDH-wildtype tumors. There were also significant differences in the composition of the tumor inflammatory microenvironment between neurotransmission-based tumor categories, with lower estimated pools of M2-phenotype macrophages in NT-1 gliomas. This multi-omics analysis of the neurotransmission expression landscape of TCGA gliomas-which highlights the existence of neurotransmission-based glioma categories with different expression, epigenetic and inflammatory profiles-supports the existence of operational neurotransmitter signaling pathways in adult gliomas. These findings could shed new light on potential vulnerabilities to exploit in future glioma-targeting drug therapies.

Identifiants

pubmed: 35455749
pii: jpm12040633
doi: 10.3390/jpm12040633
pmc: PMC9030730
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fonds de Recherche du Québec - Santé
ID : RGPIN-2022-296343

Références

Int J Mol Sci. 2018 Jan 04;19(1):
pubmed: 29300332
Nat Rev Neurol. 2016 Apr;12(4):204-16
pubmed: 26965673
Int J Oncol. 2013 Feb;42(2):757-66
pubmed: 23254855
Biomol Ther (Seoul). 2016 Jan;24(1):1-8
pubmed: 26759695
J Neurooncol. 2013 Feb;111(3):273-83
pubmed: 23263745
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Onco Targets Ther. 2015 Nov 17;8:3391-400
pubmed: 26604796
Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S89-95
pubmed: 25722938
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Expert Rev Anticancer Ther. 2011 Dec;11(12):1935-44
pubmed: 22117160
Front Genet. 2018 Oct 23;9:493
pubmed: 30405699
Biomed Pharmacother. 2018 Jan;97:1554-1563
pubmed: 29793318
Nat Cancer. 2021 Jul;2(7):723-740
pubmed: 35121943
Acta Neuropathol. 2015 Jun;129(6):809-27
pubmed: 25943885
PLoS One. 2016 Nov 28;11(11):e0167096
pubmed: 27893811
Genome Biol. 2014;15(12):550
pubmed: 25516281
Neurol Sci. 2016 Aug;37(8):1341-7
pubmed: 27215622
J Cell Biochem. 2014 Apr;115(4):772-84
pubmed: 24249161
PLoS One. 2013 Nov 14;8(11):e80865
pubmed: 24244722
Front Oncol. 2020 Jul 03;10:840
pubmed: 32719739
Exp Ther Med. 2021 Apr;21(4):300
pubmed: 33717243
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Bioinformatics. 2012 Oct 1;28(19):2520-2
pubmed: 22908215
Genome Res. 2014 Nov;24(11):1765-73
pubmed: 25135958
Nat Rev Cancer. 2021 Jan;21(1):22-36
pubmed: 33082563
J Clin Neurosci. 2014 Oct;21(10):1709-13
pubmed: 24980627
Sci Rep. 2013 Dec 05;3:3423
pubmed: 24305689
Genomics Proteomics Bioinformatics. 2021 Feb;19(1):1-12
pubmed: 33662628
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
Curr Protein Pept Sci. 2015;16(4):301-9
pubmed: 25929864
BMC Med. 2020 Oct 16;18(1):280
pubmed: 33059718
Oncol Rep. 2014 Sep;32(3):957-64
pubmed: 25017996
J Oncol. 2013;2013:486912
pubmed: 23737783
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1506-17
pubmed: 27035623
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Curr Neurol Neurosci Rep. 2013 May;13(5):345
pubmed: 23532369
Int J Mol Sci. 2020 Nov 11;21(22):
pubmed: 33187183
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Cancer Lett. 2019 Feb 28;443:108-114
pubmed: 30529154
Cell. 2021 Jul 22;184(15):4048-4063.e32
pubmed: 34233165
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Nucleic Acids Res. 1999 Jan 1;27(1):29-34
pubmed: 9847135
Nat Methods. 2019 Jul;16(7):577
pubmed: 31249418
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Neuro Oncol. 2021 Jun 1;23(6):955-966
pubmed: 33173941
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Brain Behav Immun. 2016 May;54:260-277
pubmed: 26851553
PLoS One. 2012;7(3):e32709
pubmed: 22442669
Nat Med. 2018 Aug;24(8):1192-1203
pubmed: 29988124
Clin Cancer Res. 2011 Nov 15;17(22):7105-15
pubmed: 21953503
Curr Pharm Des. 2013;19(35):6382-9
pubmed: 23865473
Ann N Y Acad Sci. 2005 Nov;1058:246-54
pubmed: 16394141
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Front Endocrinol (Lausanne). 2013 Aug 15;4:102
pubmed: 23966981
Sci Data. 2017 Mar 14;4:170024
pubmed: 28291232
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820960748
pubmed: 32945237
Sci Rep. 2017 Mar 22;7:44792
pubmed: 28327577
Nucleic Acids Res. 2020 Jan 8;48(D1):D189-D197
pubmed: 31906603
Cancer Discov. 2021 Mar;11(3):575-590
pubmed: 33558264
Contemp Oncol (Pozn). 2018;22(4):215-222
pubmed: 30783384
Neuron. 1995 Dec;15(6):1287-98
pubmed: 8845153

Auteurs

Hoang Dong Nguyen (HD)

Département de Biochimie et de Génomique Fonctionnelle, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.

Phedias Diamandis (P)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C1, Canada.
Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada.

Michelle S Scott (MS)

Département de Biochimie et de Génomique Fonctionnelle, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.

Maxime Richer (M)

Axe Neurosciences du Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval et Département de Biologie Moléculaire, Biochimie et Pathologie de l'Université Laval, Québec, QC G1V 4G2, Canada.

Classifications MeSH